Diplomat Pharmacy (DPLO) Misses Q2 EPS by 200c, Revenues Beat; Updates FY19 EPS Guidance Below Consensus, Announces Review of Strategic Alternatives
Tweet Send to a Friend
Diplomat Pharmacy (NYSE: DPLO) reported Q2 EPS of ($2.13), $2.00 worse than the analyst estimate of ($0.13). Revenue for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
